Pharmathen is a research-centred pharmaceutical company that develops complex drug delivery and formulations to enhance patient compliance while providing affordable, high-quality medicines on a global scale. Established in 1969, the company serves over 250 customers across more than 90 countries, including regions such as Europe, North America, South America, the Middle East & North Africa, and Asia-Pacific. Pharmathen's extensive portfolio comprises over 100 products, including finished dosages—such as long-acting injectables, peptides, modified-release orals, and various complex ophthalmics—as well as active pharmaceutical ingredients (APIs), particularly peptides and additional products. All offerings are manufactured in FDA and EU-approved GMP facilities.

Services include:
- Active Pharmaceutical Ingredients (APIs)
- Finished Dosage Forms
- Long-acting Injectables
- Peptides
- Modified-release Orals
- Complex Ophthalmic Products
- Regulatory support
- Technological know-how

Pharmathen is dedicated to innovation in the pharmaceutical industry and strives to meet the needs of its diverse customer base. For more information, please visit pharmathen.com.